Journal
CUREUS JOURNAL OF MEDICAL SCIENCE
Volume 11, Issue 6, Pages -Publisher
SPRINGERNATURE
DOI: 10.7759/cureus.5001
Keywords
ipilimumab; immune related adverse events; hypophysitis; melanoma
Categories
Ask authors/readers for more resources
Ipilimumab is a monoclonal antibody targeting the cytotoxic T-lymphocyte antigen-4 receptor, which was originally approved for the treatment of metastatic melanoma. It is the first immune checkpoint inhibitor to enter clinical practice. Immune toxicity due to ipilimumab causing colitis, hepatitis, and dermatitis are well-described in literature. We report a case of hypophysitis resolving with corticosteroid treatment, following which the patient developed long-term primary thyroid impairment. This highlights the importance of vigilance for rarer immune-related toxicities as clinical utilization of ipilimumab becomes more widespread.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available